

Antonio Ceriello

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1495973/antonio-ceriello-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

119 papers	11,925 citations	47 h-index	109 g-index
132 ext. papers	14,210 ext. citations	7.6 avg, IF	6.91 L-index

#	Paper	IF	Citations
119	HbA1c variability predicts cardiovascular complications in type 2 diabetes regardless of being at glycemic target.. <i>Cardiovascular Diabetology</i> , 2022 , 21, 13	8.7	1
118	Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	4
117	Managing weight and glycaemic targets in people with type 2 diabetes-How far have we come?. <i>Endocrinology, Diabetes and Metabolism</i> , 2022 , e00330	2.7	0
116	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes.. <i>Nature Communications</i> , 2022 , 13, 2318	17.4	4
115	Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin.. <i>Cellular and Molecular Life Sciences</i> , 2022 , 79, 273	10.3	2
114	Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. <i>Cardiovascular Diabetology</i> , 2021 , 20, 218	8.7	7
113	Glycaemic management in diabetes: old and new approaches. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 ,	18.1	9
112	Positioning newer drugs in the management of type 2 diabetes. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 , 9, 138-139	18.1	3
111	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 92	8.7	8
110	Tackling the pillars of ageing to fight COVID-19. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e191	9.5	4
109	DPP-4 Inhibitors Have Different Effects on Endothelial Low-Grade Inflammation and on the M1-M2 Macrophage Polarization Under Hyperglycemic Conditions. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2021 , 14, 1519-1531	3.4	5
108	Variability of risk factors and diabetes complications. <i>Cardiovascular Diabetology</i> , 2021 , 20, 101	8.7	5
107	Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation. <i>ClinicoEconomics and Outcomes Research</i> , 2021 , 13, 453-464	1.7	1
106	Elevated HbA1c levels in pre-Covid-19 infection increases the risk of mortality: A sistematic review and meta-analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , e3476	7.5	9
105	Pharmacological management of COVID-19 in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107927	3.2	7
104	Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. <i>Metabolism: Clinical and Experimental</i> , 2021 , 120, 154799	12.7	9
103	Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3379	7.5	10

102	CD31 Extracellular Vesicles From Patients With Type 2 Diabetes Shuttle a miRNA Signature Associated With Cardiovascular Complications. <i>Diabetes</i> , 2021 , 70, 240-254	0.9	19
101	Variability in body weight and the risk of cardiovascular complications in type 2 diabetes: results from the Swedish National Diabetes Register. <i>Cardiovascular Diabetology</i> , 2021 , 20, 173	8.7	4
100	Dietary Glycaemic Index Labelling: A Global Perspective. <i>Nutrients</i> , 2021 , 13,	6.7	4
99	Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. <i>Theranostics</i> , 2021 , 11, 1031-1045	12.1	20
98	Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1696-1700	6.7	25
97	Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era. <i>Diabetes Care</i> , 2020 , 43, 1427-1432	14.6	47
96	Glucose Variability and Diabetic Complications: Is It Time to Treat?. <i>Diabetes Care</i> , 2020 , 43, 1169-1171	14.6	23
95	Why is hyperglycaemia worsening COVID-19 and its prognosis?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1951-1952	6.7	46
94	Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. <i>Metabolism: Clinical and Experimental</i> , 2020 , 110, 154308	12.7	19
93	Small extracellular vesicles deliver miR-21 and miR-217 as pro-senescence effectors to endothelial cells. <i>Journal of Extracellular Vesicles</i> , 2020 , 9, 1725285	16.4	63
92	The Need for Diabetes Care Customization in the ICU at the Time of SARS-CoV-2 Outbreak. <i>Diabetes Therapy</i> , 2020 , 11, 1-3	3.6	5
91	COVID-19 infection in Italian people with diabetes: Lessons learned for our future (an experience to be used). <i>Diabetes Research and Clinical Practice</i> , 2020 , 162, 108137	7.4	55
90	COVID-19 and diabetes management: What should be considered?. <i>Diabetes Research and Clinical Practice</i> , 2020 , 163, 108151	7.4	63
89	Two drugs are better than one to start T2DM therapy. <i>Nature Reviews Endocrinology</i> , 2020 , 16, 15-16	15.2	9
88	Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , 2020 , 19, 176	8.7	11
87	Diabetes, D-dimer and COVID-19: The possible role of glucose control. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 1987	8.9	4
86	Issues for the management of people with diabetes and COVID-19 in ICU. <i>Cardiovascular Diabetology</i> , 2020 , 19, 114	8.7	23
85	COVID-19, ketoacidosis and new-onset diabetes: Are there possible cause and effect relationships among them?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2507-2508	6.7	18

84	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360
83	Type 2 Diabetes: How Much of an Autoimmune Disease?. <i>Frontiers in Endocrinology</i> , 2019 , 10, 451	5.7	42
82	Dietary Glycemic Index and Load and the Risk of Type 2 Diabetes: A Systematic Review and Updated Meta-Analyses of Prospective Cohort Studies. <i>Nutrients</i> , 2019 , 11,	6.7	87
81	The Unique Pharmacological and Pharmacokinetic Profile of Tenueligliptin: Implications for Clinical Practice. <i>Drugs</i> , 2019 , 79, 733-750	12.1	16
80	Glycaemic variability in diabetes: clinical and therapeutic implications. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 221-230	18.1	201
79	Extracellular vesicles circulating in young organisms promote healthy longevity. <i>Journal of Extracellular Vesicles</i> , 2019 , 8, 1656044	16.4	25
78	Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 25-32	3.9	133
77	The link between diabetes and atherosclerosis. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 15-24	3.9	43
76	Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention. <i>Cardiovascular Diabetology</i> , 2019 , 18, 147	8.7	23
75	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 73-80	3.9	39
74	Targets for blood glucose: What have the trials told us. <i>European Journal of Preventive Cardiology</i> , 2019 , 26, 64-72	3.9	6
73	Short-term sustained hyperglycaemia fosters an archetypal senescence-associated secretory phenotype in endothelial cells and macrophages. <i>Redox Biology</i> , 2018 , 15, 170-181	11.3	69
72	Inflammageing and metaflammation: The yin and yang of type 2 diabetes. <i>Ageing Research Reviews</i> , 2018 , 41, 1-17	12	117
71	Use of oral antidiabetic drugs in the treatment of maturity-onset diabetes of the young: A mini review. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e2940	7.5	16
70	Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low-grade inflammation the neglected component?. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2515-2522	6.7	62
69	Glucose-sensing microRNA-21 disrupts ROS homeostasis and impairs antioxidant responses in cellular glucose variability. <i>Cardiovascular Diabetology</i> , 2018 , 17, 105	8.7	47
68	Tenueligliptin enhances the beneficial effects of GLP-1 in endothelial cells exposed to hyperglycemic conditions. <i>Oncotarget</i> , 2018 , 9, 8898-8910	3.3	10
67	Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing. <i>Ageing Research Reviews</i> , 2018 , 48, 87-98	12	54

66	Exosome-based immunomodulation during aging: A nano-perspective on inflamm-aging. <i>Mechanisms of Ageing and Development</i> , 2017 , 168, 44-53	5.6	51
65	Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. <i>International Journal of Cardiology</i> , 2017 , 241, 302-310	3.2	18
64	Updates on cardiovascular outcome trials in diabetes. <i>Cardiovascular Diabetology</i> , 2017 , 16, 128	8.7	36
63	The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. <i>Endocrine</i> , 2017 , 56, 509-520	4	41
62	The "Metabolic Memory" Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. <i>Nutrients</i> , 2017 , 9,	6.7	116
61	Lipodistrophy and Associated Risk Factors in Insulin-Treated People With Diabetes. <i>International Journal of Endocrinology and Metabolism</i> , 2016 , 14, e33997	1.8	8
60	Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. <i>Cardiovascular Diabetology</i> , 2016 , 15, 71	8.7	46
59	The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2016 , 114, 64-8	7.4	7
58	The pivotal role of high glucose-induced overexpression of PKC ϵ in the appearance of glucagon-like peptide-1 resistance in endothelial cells. <i>Endocrine</i> , 2016 , 54, 396-410	4	9
57	Insulin treatment of people with diabetes mellitus and chronic liver disease. <i>Annals of Hepatology</i> , 2016 , 15, 287-8	3.1	1
56	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. <i>Diabetes Therapy</i> , 2015 , 6, 239-56	3.6	64
55	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. <i>BMJ Open Diabetes Research and Care</i> , 2015 , 3, e000109	4.5	4
54	Short-term high glucose exposure impairs insulin signaling in endothelial cells. <i>Cardiovascular Diabetology</i> , 2015 , 14, 114	8.7	32
53	GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress. <i>Therapeutics and Clinical Risk Management</i> , 2015 , 11, 901-3	3.9	10
52	DPP-4 inhibitors: pharmacological differences and their clinical implications. <i>Expert Opinion on Drug Safety</i> , 2014 , 13 Suppl 1, S57-68	4.1	562
51	Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 129-36	2.1	10
50	Glycaemic index: did Health Canada get it wrong? Position from the International Carbohydrate Quality Consortium (ICQC). <i>British Journal of Nutrition</i> , 2014 , 111, 380-2	3.6	9
49	The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. <i>Cardiovascular Diabetology</i> , 2014 , 13, 140	8.7	43

48	Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes. <i>Diabetes Care</i> , 2013 , 36, 2346-50	14.6	122
47	Type 1 diabetes and cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2013 , 12, 156	8.7	69
46	The emerging challenge in diabetes: the "metabolic memory". <i>Vascular Pharmacology</i> , 2012 , 57, 133-8	5.9	106
45	Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. <i>Diabetes</i> , 2012 , 61, 2993-7	0.9	108
44	The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes. <i>Diabetes Care</i> , 2011 , 34, 697-702	14.6	102
43	Antioxidant anti-inflammatory treatment in type 2 diabetes. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S232-6	14.6	114
42	Long-term glycemic control influences the long-lasting effect of hyperglycemia on endothelial function in type 1 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 2751-6	5.6	50
41	Administration of a new diabetes-specific enteral formula results in an improved 24h glucose profile in type 2 diabetic patients. <i>Diabetes Research and Clinical Practice</i> , 2009 , 84, 259-66	7.4	24
40	Lowering glucose to prevent adverse cardiovascular outcomes in a critical care setting. <i>Journal of the American College of Cardiology</i> , 2009 , 53, S9-13	15.1	32
39	Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 410-5	5.6	293
38	Does postprandial blood glucose matter and why?. <i>Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion</i> , 2009 , 56 Suppl 4, 8-11		3
37	Glucose "peak" and glucose "spike": Impact on endothelial function and oxidative stress. <i>Diabetes Research and Clinical Practice</i> , 2008 , 82, 262-7	7.4	71
36	Guideline for management of postmeal glucose. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2008 , 18, S17-33	4.5	83
35	Possible role of oxidative stress in the pathogenesis of hypertension. <i>Diabetes Care</i> , 2008 , 31 Suppl 2, S181-4	14.6	143
34	Cardiovascular effects of acute hyperglycaemia: pathophysiological underpinnings. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 260-8	3.3	59
33	Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2008 , 24, 103-8	7.5	16
32	Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. <i>Diabetes/Metabolism Research and Reviews</i> , 2008 , 24, 14-26	7.5	77
31	Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. <i>Diabetes</i> , 2008 , 57, 1349-54	0.9	762

30	Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. <i>Journal of Diabetes and Its Complications</i> , 2007 , 21, 20-7	3.2	12
29	Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. <i>Diabetes Care</i> , 2007 , 30, 1694-8	14.6	40
28	Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications. <i>Current Nutrition and Food Science</i> , 2007 , 3, 194-199	0.7	3
27	Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. <i>Diabetes Care</i> , 2007 , 30, 649-54	14.6	84
26	Effects of macronutrient excess and composition on oxidative stress: relevance to diabetes and cardiovascular disease. <i>Current Atherosclerosis Reports</i> , 2006 , 8, 472-6	6	15
25	Effects of gliclazide beyond metabolic control. <i>Metabolism: Clinical and Experimental</i> , 2006 , 55, S10-5	12.7	9
24	Oxidative stress and diabetes-associated complications. <i>Endocrine Practice</i> , 2006 , 12 Suppl 1, 60-2	3.2	162
23	Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006 , 16, 453-6	4.5	109
22	Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes. <i>Current Opinion in Lipidology</i> , 2006 , 17, 510-8	4.4	52
21	Acute hyperglycaemia: a new risk factor during myocardial infarction. <i>European Heart Journal</i> , 2005 , 26, 328-31	9.5	101
20	PROactive Study: (r)evolution in the therapy of diabetes?. <i>Diabetic Medicine</i> , 2005 , 22, 1463-4	3.5	10
19	Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. <i>Diabetes Care</i> , 2005 , 28, 632-7	14.6	58
18	Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. <i>Circulation</i> , 2005 , 111, 2518-24	16.7	243
17	Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 816-23	9.4	990
16	Postprandial glucose regulation and diabetic complications. <i>Archives of Internal Medicine</i> , 2004 , 164, 2090-5		251
15	Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. <i>American Heart Journal</i> , 2004 , 147, 803-7	4.9	91
14	New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. <i>Diabetes Care</i> , 2003 , 26, 1589-96	14.6	566
13	Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. <i>Diabetes</i> , 2002 , 51, 1076-82	0.9	237

12	Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. <i>Circulation</i> , 2002 , 106, 2067-72	16.7	1425
11	Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. <i>Circulation</i> , 2002 , 106, 1211-8	16.7	545
10	Role of hyperglycemia in nitrotyrosine postprandial generation. <i>Diabetes Care</i> , 2002 , 25, 1439-43	14.6	210
9	Oxidative stress evaluation in diabetes. <i>Diabetes Technology and Therapeutics</i> , 2000 , 2, 589-600	8.1	46
8	The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications. <i>Diabetic Medicine</i> , 1998 , 15, 188-93	3.5	137
7	The emerging role of post-prandial hyperglycaemic spikes in the pathogenesis of diabetic complications 1998 , 15, 188		10
6	Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. <i>Diabetes</i> , 1995 , 44, 924-8	0.9	148
5	Fibrinogen Plasma Levels as a Marker of Thrombin Activation: New Insights on the Role of Fibrinogen as a Cardiovascular Risk Factor. <i>Thrombosis and Haemostasis</i> , 1994 , 71, 593-595	7	28
4	Macromolecular Protein Complex: A New Way to Understand the Fibrinogen Lowering Effect of Glycosaminoglycans?. <i>Thrombosis and Haemostasis</i> , 1994 , 72, 985-986	7	
3	Hyperglycemia may determine fibrinopeptide A plasma level increase in humans. <i>Metabolism: Clinical and Experimental</i> , 1989 , 38, 1162-3	12.7	37
2	Influence of labile glucose adducts on glycosylated protein assay by aminophenylboronic acid affinity chromatography: in vivo studies. <i>Acta Diabetologica Latina</i> , 1985 , 22, 81-2		2
1	Death by SARS-CoV 2 - a Romanian COVID-19 multi-centre comorbidity study		3